You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDoxazosin
Accession NumberDB00590  (APRD00474)
TypeSmall Molecule
GroupsApproved
DescriptionDoxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors. It may be used to mild to moderate hypertension and in the management of symptomatic benign prostatic hyperplasia (BPH). α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland.
Structure
Thumb
Synonyms
1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
Doxazosina
Doxazosine
Doxazosinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CarduraTablet4 mg/1OralRoerig1990-11-02Not applicableUs
CarduraTablet8 mg/1OralRoerig1990-11-02Not applicableUs
CarduraTablet1 mg/1OralRoerig1990-11-02Not applicableUs
CarduraTablet2 mg/1OralRoerig1990-11-02Not applicableUs
Cardura XLTablet, multilayer, extended release4 mg/1OralRoerig2005-02-22Not applicableUs
Cardura XLTablet, multilayer, extended release8 mg/1OralRoerig2005-02-22Not applicableUs
Cardura-1 Tab 1mgTablet1 mgOralPfizer Canada Inc1992-12-31Not applicableCanada
Cardura-2 Tab 2mgTablet2 mgOralPfizer Canada Inc1992-12-31Not applicableCanada
Cardura-4 Tab 4mgTablet4 mgOralPfizer Canada Inc1992-12-31Not applicableCanada
Dom-doxazosinTablet2 mgOralDominion Pharmacal2004-05-26Not applicableCanada
Dom-doxazosinTablet4 mgOralDominion Pharmacal2004-05-26Not applicableCanada
Dom-doxazosinTablet1 mgOralDominion Pharmacal2004-05-26Not applicableCanada
Doxazosin MesylateTablet4 mg/1OralGreenstone LLC2014-07-07Not applicableUs
Doxazosin MesylateTablet8 mg/1OralGreenstone LLC2014-07-07Not applicableUs
Doxazosin MesylateTablet1 mg/1OralREMEDYREPACK INC.2015-11-12Not applicableUs
Doxazosin MesylateTablet4 mg/1OralREMEDYREPACK INC.2016-01-14Not applicableUs
Doxazosin MesylateTablet1 mg/1OralGreenstone LLC2014-07-07Not applicableUs
Doxazosin MesylateTablet2 mg/1OralGreenstone LLC2014-07-07Not applicableUs
Doxazosin-1Tablet1 mgOralPro Doc Limitee2000-05-10Not applicableCanada
Doxazosin-2Tablet2 mgOralPro Doc Limitee2000-05-10Not applicableCanada
Doxazosin-4Tablet4 mgOralPro Doc Limitee2000-05-10Not applicableCanada
Mylan-doxazosinTablet2 mgOralMylan Pharmaceuticals Ulc1999-07-16Not applicableCanada
Mylan-doxazosinTablet4 mgOralMylan Pharmaceuticals Ulc1999-07-16Not applicableCanada
Mylan-doxazosinTablet1 mgOralMylan Pharmaceuticals Ulc1999-07-16Not applicableCanada
PMS-doxazosinTablet1 mgOralPharmascience Inc2001-10-01Not applicableCanada
PMS-doxazosinTablet2 mgOralPharmascience Inc2001-10-01Not applicableCanada
PMS-doxazosinTablet4 mgOralPharmascience Inc2001-10-01Not applicableCanada
Ratio-doxazosinTablet2 mgOralRatiopharm Inc Division Of Teva Canada Limited2001-02-132006-08-04Canada
Ratio-doxazosinTablet4 mgOralRatiopharm Inc Division Of Teva Canada Limited2001-02-132006-08-04Canada
Ratio-doxazosinTablet1 mgOralRatiopharm Inc Division Of Teva Canada Limited2001-02-132006-08-04Canada
Teva-doxazosinTablet1 mgOralTeva Canada Limited2000-09-01Not applicableCanada
Teva-doxazosinTablet2 mgOralTeva Canada Limited2000-09-01Not applicableCanada
Teva-doxazosinTablet4 mgOralTeva Canada Limited2000-09-01Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-doxazosinTablet1 mgOralApotex Inc1999-07-22Not applicableCanada
Apo-doxazosinTablet2 mgOralApotex Inc1999-07-22Not applicableCanada
Apo-doxazosinTablet4 mgOralApotex Inc1999-07-22Not applicableCanada
DoxazosinTablet4 mg/1OralAmerican Health Packaging2014-09-22Not applicableUs
DoxazosinTablet1 mg/1OralMylan Pharmaceuticals Inc.2000-10-20Not applicableUs
DoxazosinTablet2 mg/1OralCardinal Health2011-08-18Not applicableUs
DoxazosinTablet8 mg/1OralNu Care Pharmaceuticals, Inc.2015-04-22Not applicableUs
DoxazosinTablet2 mg/1OralCardinal Health2000-10-20Not applicableUs
DoxazosinTablet4 mg/1OralREMEDYREPACK INC.2015-12-10Not applicableUs
DoxazosinTablet1 mg/1OralAccord Healthcare Inc.2015-03-04Not applicableUs
DoxazosinTablet2 mg/1OralPreferred Pharmaceuticals, Inc.2013-06-24Not applicableUs
DoxazosinTablet1 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2000-10-19Not applicableUs
DoxazosinTablet2 mg/1OralMylan Institutional Inc.2001-01-01Not applicableUs
DoxazosinTablet2 mg/1OralRebel Distributors Corp2011-03-08Not applicableUs
DoxazosinTablet4 mg/1OralREMEDYREPACK INC.2013-05-23Not applicableUs
DoxazosinTablet8 mg/1OralPhysicians Total Care, Inc.2003-04-03Not applicableUs
DoxazosinTablet2 mg/1OralLake Erie Medical DBA Quality Care Products LLC2000-10-20Not applicableUs
DoxazosinTablet1 mg/1OralREMEDYREPACK INC.2014-12-01Not applicableUs
DoxazosinTablet8 mg/1OralLegacy Pharmaceutical Packaging2011-07-14Not applicableUs
DoxazosinTablet1 mg/1OralMajor Pharmaceuticals2011-07-14Not applicableUs
DoxazosinTablet8 mg/1OralApotex Corp.2011-07-14Not applicableUs
DoxazosinTablet8 mg/1OralA S Medication Solutions2015-04-22Not applicableUs
DoxazosinTablet8 mg/1OralREMEDYREPACK INC.2013-05-132016-04-05Us
DoxazosinTablet2 mg/1OralAphena Pharma Solutions Tennessee, Llc2000-10-20Not applicableUs
DoxazosinTablet8 mg/1OralAphena Pharma Solutions Tennessee, Llc2000-10-20Not applicableUs
DoxazosinTablet4 mg/1OralTeva Pharmaceuticals Usa, Inc.2014-09-09Not applicableUs
DoxazosinTablet4 mg/1OralUnit Dose Services2000-10-20Not applicableUs
DoxazosinTablet4 mg/1OralA S Medication Solutions2011-07-14Not applicableUs
DoxazosinTablet4 mg/1OralA S Medication Solutions2015-04-22Not applicableUs
DoxazosinTablet4 mg/1OralSt Marys Medical Park Pharmacy2013-05-02Not applicableUs
DoxazosinTablet2 mg/1OralMylan Pharmaceuticals Inc.2000-10-20Not applicableUs
DoxazosinTablet1 mg/1OralApotex Corp.2011-07-14Not applicableUs
DoxazosinTablet1 mg/1OralA S Medication Solutions2015-03-04Not applicableUs
DoxazosinTablet4 mg/1OralMylan Institutional Inc.2001-01-01Not applicableUs
DoxazosinTablet2 mg/1OralAv Kare, Inc.2015-04-09Not applicableUs
DoxazosinTablet4 mg/1OralCardinal Health2000-10-20Not applicableUs
DoxazosinTablet8 mg/1Oralbryant ranch prepack2011-05-27Not applicableUs
DoxazosinTablet2 mg/1OralAccord Healthcare Inc.2015-03-24Not applicableUs
DoxazosinTablet1 mg/1OralA S Medication Solutions2000-10-20Not applicableUs
DoxazosinTablet2 mg/1OralUnit Dose Services2015-04-22Not applicableUs
DoxazosinTablet8 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2000-10-19Not applicableUs
DoxazosinTablet4 mg/1OralAidarex Pharmaceuticals LLC2011-10-27Not applicableUs
DoxazosinTablet2 mg/1OralPhysicians Total Care, Inc.2003-05-28Not applicableUs
DoxazosinTablet8 mg/1OralUnit Dose Services2000-10-20Not applicableUs
DoxazosinTablet2 mg/1OralPreferred Pharmaceuticals, Inc2011-03-08Not applicableUs
DoxazosinTablet2 mg/1OralMajor Pharmaceuticals2011-07-14Not applicableUs
DoxazosinTablet4 mg/1OralUnit Dose Services2015-04-22Not applicableUs
DoxazosinTablet2 mg/1OralREMEDYREPACK INC.2014-02-03Not applicableUs
DoxazosinTablet4 mg/1OralAphena Pharma Solutions Tennessee, Llc2000-10-20Not applicableUs
DoxazosinTablet1 mg/1OralAmerican Health Packaging2014-09-22Not applicableUs
DoxazosinTablet2 mg/1OralTeva Pharmaceuticals Usa, Inc.2014-08-06Not applicableUs
DoxazosinTablet1 mg/1OralCardinal Health2011-08-18Not applicableUs
DoxazosinTablet8 mg/1OralA S Medication Solutions2011-07-14Not applicableUs
DoxazosinTablet2 mg/1OralA S Medication Solutions2015-04-22Not applicableUs
DoxazosinTablet4 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
DoxazosinTablet2 mg/1OralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
DoxazosinTablet2 mg/1OralLegacy Pharmaceutical Packaging2011-07-14Not applicableUs
DoxazosinTablet4 mg/1OralMylan Pharmaceuticals Inc.2000-10-20Not applicableUs
DoxazosinTablet2 mg/1OralApotex Corp.2011-07-14Not applicableUs
DoxazosinTablet2 mg/1OralA S Medication Solutions2011-07-14Not applicableUs
DoxazosinTablet2 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2000-10-19Not applicableUs
DoxazosinTablet2 mg/1OralREMEDYREPACK INC.2013-02-252016-03-31Us
DoxazosinTablet4 mg/1OralAv Kare, Inc.2015-04-09Not applicableUs
DoxazosinTablet2 mg/1OralPd Rx Pharmaceuticals, Inc.2011-10-27Not applicableUs
DoxazosinTablet4 mg/1Oralbryant ranch prepack2011-03-08Not applicableUs
DoxazosinTablet4 mg/1OralAccord Healthcare Inc.2015-03-24Not applicableUs
DoxazosinTablet1 mg/1OralA S Medication Solutions2011-07-14Not applicableUs
DoxazosinTablet1 mg/1OralA S Medication Solutions2015-03-04Not applicableUs
DoxazosinTablet4 mg/1OralLake Erie Medical DBA Quality Care Products LLC2000-10-20Not applicableUs
DoxazosinTablet4 mg/1OralPhysicians Total Care, Inc.2003-05-28Not applicableUs
DoxazosinTablet8 mg/1OralUnit Dose Services2000-10-20Not applicableUs
DoxazosinTablet4 mg/1OralREMEDYREPACK INC.2015-06-01Not applicableUs
DoxazosinTablet4 mg/1OralPreferred Pharmaceuticals, Inc2011-03-08Not applicableUs
DoxazosinTablet4 mg/1OralMajor Pharmaceuticals2011-07-14Not applicableUs
DoxazosinTablet8 mg/1OralUnit Dose Services2015-04-22Not applicableUs
DoxazosinTablet4 mg/1OralNu Care Pharmaceuticals, Inc.2015-04-22Not applicableUs
DoxazosinTablet2 mg/1OralAmerican Health Packaging2014-09-22Not applicableUs
DoxazosinTablet1 mg/1OralTeva Pharmaceuticals Usa, Inc.2014-08-06Not applicableUs
DoxazosinTablet4 mg/1OralCardinal Health2011-08-18Not applicableUs
DoxazosinTablet4 mg/1OralStat Rx USA2009-10-27Not applicableUs
DoxazosinTablet8 mg/1OralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
DoxazosinTablet4 mg/1OralLegacy Pharmaceutical Packaging2011-07-14Not applicableUs
DoxazosinTablet8 mg/1OralMylan Pharmaceuticals Inc.2000-10-20Not applicableUs
DoxazosinTablet4 mg/1OralApotex Corp.2011-07-14Not applicableUs
DoxazosinTablet4 mg/1OralA S Medication Solutions2015-04-22Not applicableUs
DoxazosinTablet4 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2000-10-19Not applicableUs
DoxazosinTablet4 mg/1OralREMEDYREPACK INC.2013-03-142016-10-13Us
DoxazosinTablet8 mg/1OralAv Kare, Inc.2015-04-09Not applicableUs
DoxazosinTablet4 mg/1OralPd Rx Pharmaceuticals, Inc.2011-10-27Not applicableUs
DoxazosinTablet2 mg/1Oralbryant ranch prepack2011-03-08Not applicableUs
DoxazosinTablet8 mg/1OralTeva Pharmaceuticals Usa, Inc.2014-12-05Not applicableUs
DoxazosinTablet8 mg/1OralAccord Healthcare Inc.2015-03-24Not applicableUs
DoxazosinTablet2 mg/1OralA S Medication Solutions2011-07-14Not applicableUs
DoxazosinTablet8 mg/1OralA S Medication Solutions2015-04-22Not applicableUs
DoxazosinTablet8 mg/1OralLake Erie Medical DBA Quality Care Products LLC2000-10-20Not applicableUs
DoxazosinTablet1 mg/1OralPhysicians Total Care, Inc.2003-08-14Not applicableUs
DoxazosinTablet1 mg/1OralMylan Institutional Inc.2001-01-01Not applicableUs
DoxazosinTablet2 mg/1OralREMEDYREPACK INC.2015-11-12Not applicableUs
DoxazosinTablet8 mg/1OralTeva Pharmaceuticals USA Inc2000-10-202015-10-31Us
DoxazosinTablet8 mg/1OralMajor Pharmaceuticals2011-07-14Not applicableUs
Doxazosin MesylateTablet4 mg/1OralA S Medication Solutions2004-06-10Not applicableUs
Doxazosin MesylateTablet8 mg/1OralMajor Pharmaceuticals2010-04-28Not applicableUs
Doxazosin MesylateTablet8 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Doxazosin MesylateTablet4 mg/1OralREMEDYREPACK INC.2011-05-09Not applicableUs
Doxazosin MesylateTablet8 mg/1OralGolden State Medical Supply, Inc.2004-06-10Not applicableUs
Doxazosin MesylateTablet8 mg/1OralDAVA Pharmaceuticals, Inc.2004-06-10Not applicableUs
Doxazosin MesylateTablet1 mg/1OralMajor Pharmaceuticals2010-05-06Not applicableUs
Doxazosin MesylateTablet1 mg/1OralGolden State Medical Supply, Inc.2004-06-10Not applicableUs
Doxazosin MesylateTablet4 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Doxazosin MesylateTablet2 mg/1OralREMEDYREPACK INC.2011-03-31Not applicableUs
Doxazosin MesylateTablet1 mg/1OralDispensing Solutions, Inc.2004-06-10Not applicableUs
Doxazosin MesylateTablet4 mg/1OralBlenheim Pharmacal, Inc.2013-12-10Not applicableUs
Doxazosin MesylateTablet1 mg/1OralREMEDYREPACK INC.2015-04-14Not applicableUs
Doxazosin MesylateTablet1 mg/1OralDAVA Pharmaceuticals, Inc.2004-06-10Not applicableUs
Doxazosin MesylateTablet2 mg/1OralMajor Pharmaceuticals2010-04-28Not applicableUs
Doxazosin MesylateTablet2 mg/1OralGolden State Medical Supply, Inc.2004-06-10Not applicableUs
Doxazosin MesylateTablet1 mg/1OralBlenheim Pharmacal, Inc.2013-12-10Not applicableUs
Doxazosin MesylateTablet1 mg/1OralREMEDYREPACK INC.2011-06-06Not applicableUs
Doxazosin MesylateTablet2 mg/1OralDAVA Pharmaceuticals, Inc.2004-06-10Not applicableUs
Doxazosin MesylateTablet8 mg/1OralA S Medication Solutions2004-06-10Not applicableUs
Doxazosin MesylateTablet4 mg/1OralMajor Pharmaceuticals2010-04-28Not applicableUs
Doxazosin MesylateTablet2 mg/1OralREMEDYREPACK INC.2014-05-27Not applicableUs
Doxazosin MesylateTablet1 mg/1OralREMEDYREPACK INC.2010-07-29Not applicableUs
Doxazosin MesylateTablet4 mg/1OralGolden State Medical Supply, Inc.2004-06-10Not applicableUs
Doxazosin MesylateTablet2 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Doxazosin MesylateTablet1 mg/1OralREMEDYREPACK INC.2011-11-162016-11-03Us
Doxazosin MesylateTablet4 mg/1OralDAVA Pharmaceuticals, Inc.2004-06-10Not applicableUs
Doxazosin MesylateTablet1 mg/1OralA S Medication Solutions2004-06-10Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlfadilPfizer (Sweden)
CardenalinPfizer (Japan; discontinued)
CardularPfizer (Germany)
Cardura-1Pfizer (Canada)
Cardura-2Pfizer (Canada)
Cardura-4Pfizer (Canada)
CarduranPfizer (Brazil, Denmark, Norway, Spain)
DiblocinAstraZeneca (Germany)
NormothenBioindustria (Italy)
SupressinPfizer (Austria)
Brand mixtures
NameLabellerIngredients
Cardura-1,2,and 4Astrazeneca Canada Inc
Salts
Name/CASStructureProperties
Doxazosin mesylate
77883-43-3
Thumb
  • InChI Key: VJECBOKJABCYMF-UHFFFAOYSA-N
  • Monoisotopic Mass: 547.173684088
  • Average Mass: 547.58
DBSALT001948
Categories
UNIINW1291F1W8
CAS number74191-85-8
WeightAverage: 451.4751
Monoisotopic: 451.185568935
Chemical FormulaC23H25N5O5
InChI KeyRUZYUOTYCVRMRZ-UHFFFAOYSA-N
InChI
InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)
IUPAC Name
2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
SMILES
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1
Pharmacology
IndicationFor treatment and management of mild to moderate hypertension and urinary obstruction symptoms caused by BPH.
Structured Indications
PharmacodynamicsDoxazosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Doxazosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Doxazosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1a adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Doxazosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Doxazosin results from a decrease in systemic vascular resistance and the parent compound Doxazosin is primarily responsible for the antihypertensive activity.
Mechanism of actionDoxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-1A adrenergic receptorProteinyes
antagonist
HumanP35348 details
Alpha-1B adrenergic receptorProteinyes
antagonist
HumanP35368 details
Alpha-1D adrenergic receptorProteinyes
antagonist
HumanP25100 details
Potassium voltage-gated channel subfamily H member 2Proteinunknown
inhibitor
HumanQ12809 details
Potassium voltage-gated channel subfamily H member 6Proteinunknown
inhibitor
HumanQ9H252 details
Potassium voltage-gated channel subfamily H member 7Proteinunknown
inhibitor
HumanQ9NS40 details
Related Articles
Absorption65%
Volume of distributionNot Available
Protein binding98%
Metabolism

Hepatic.

Route of eliminationOn average only 4.8% of the dose was excreted as unchanged drug in the feces and only a trace of the total radioactivity in the urine was attributed to unchanged drug.
Half life22 hours
ClearanceNot Available
ToxicitySymptoms of overdose include hypotension. Oral LD50 is greater than 1000 mg/kg in mice and rats.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Doxazosin.Experimental
AbirateroneThe serum concentration of Doxazosin can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Doxazosin.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Doxazosin.Approved, Vet Approved
AdrafinilDoxazosin may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Doxazosin.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Doxazosin.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Doxazosin.Experimental
AlfuzosinAlfuzosin may increase the hypotensive activities of Doxazosin.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Doxazosin is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Doxazosin.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Doxazosin.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Doxazosin.Approved, Investigational
AmifostineDoxazosin may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Amiloride.Approved
AmiodaroneThe metabolism of Doxazosin can be decreased when combined with Amiodarone.Approved, Investigational
AmitrazDoxazosin may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Doxazosin.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Doxazosin.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Doxazosin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Doxazosin is combined with Amphotericin B.Approved, Investigational
AmrinoneDoxazosin may increase the hypotensive activities of Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Doxazosin is combined with Amyl Nitrite.Approved
AnisodamineDoxazosin may decrease the vasoconstricting activities of Anisodamine.Investigational
Aop200704Aop200704 may increase the orthostatic hypotensive activities of Doxazosin.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Doxazosin.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Apraclonidine.Approved
ArbutamineDoxazosin may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolDoxazosin may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Doxazosin.Approved, Investigational
ArmodafinilThe metabolism of Doxazosin can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Doxazosin.Approved, Investigational
ArtemetherThe metabolism of Doxazosin can be decreased when combined with Artemether.Approved
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Doxazosin.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
AtomoxetineThe metabolism of Doxazosin can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Doxazosin.Approved, Investigational
AzelnidipineDoxazosin may increase the hypotensive activities of Azelnidipine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Azilsartan medoxomil.Approved
AzimilideDoxazosin may increase the hypotensive activities of Azimilide.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Doxazosin.Experimental
BarbitalBarbital may increase the hypotensive activities of Doxazosin.Illicit
BarnidipineDoxazosin may increase the hypotensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Doxazosin.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Doxazosin.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Doxazosin.Approved
BenidipineDoxazosin may increase the hypotensive activities of Benidipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Doxazosin.Withdrawn
BepridilDoxazosin may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Doxazosin.Approved, Vet Approved
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
BethanidineBethanidine may increase the hypotensive activities of Doxazosin.Approved
BevantololBevantolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
BimatoprostDoxazosin may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
BitolterolDoxazosin may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BoceprevirThe serum concentration of Doxazosin can be increased when it is combined with Boceprevir.Approved
BopindololBopindolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
BortezomibThe metabolism of Doxazosin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Doxazosin.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Doxazosin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Doxazosin.Approved
BretyliumThe risk or severity of adverse effects can be increased when Doxazosin is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Doxazosin.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Doxazosin.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Doxazosin.Approved, Investigational
BucindololDoxazosin may increase the antihypertensive activities of Bucindolol.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Doxazosin.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Bupivacaine.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
BupropionThe metabolism of Doxazosin can be decreased when combined with Bupropion.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Doxazosin.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Doxazosin.Approved
CaiDoxazosin may increase the hypotensive activities of Cai.Investigational
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Doxazosin.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Doxazosin is combined with Candesartan.Approved
CandoxatrilDoxazosin may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Captopril.Approved
CarbamazepineThe metabolism of Doxazosin can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Carbetocin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Doxazosin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Doxazosin.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
CarvedilolDoxazosin may increase the antihypertensive activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Doxazosin can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Doxazosin.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Doxazosin.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Doxazosin.Withdrawn
ChloramphenicolThe metabolism of Doxazosin can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Doxazosin can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Doxazosin.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Doxazosin.Approved
CholecalciferolThe metabolism of Doxazosin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Cilazapril.Approved
CilnidipineDoxazosin may increase the hypotensive activities of Cilnidipine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Doxazosin.Approved
CinacalcetThe metabolism of Doxazosin can be decreased when combined with Cinacalcet.Approved
CinnarizineDoxazosin may increase the hypotensive activities of Cinnarizine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Doxazosin.Approved, Investigational
CirazolineDoxazosin may decrease the vasoconstricting activities of Cirazoline.Experimental
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Doxazosin.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Doxazosin.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Doxazosin.Approved
ClemastineThe metabolism of Doxazosin can be decreased when combined with Clemastine.Approved
ClenbuterolDoxazosin may decrease the vasoconstricting activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Doxazosin.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Clofarabine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Doxazosin.Approved, Investigational
ClomipramineThe metabolism of Doxazosin can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Doxazosin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Doxazosin.Approved, Nutraceutical
ClotrimazoleThe metabolism of Doxazosin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Doxazosin.Approved
CobicistatThe serum concentration of Doxazosin can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Doxazosin.Approved
CocaineThe metabolism of Doxazosin can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Doxazosin.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Doxazosin is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Doxazosin.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Doxazosin.Approved
CryptenamineDoxazosin may increase the hypotensive activities of Cryptenamine.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Doxazosin.Approved, Investigational, Vet Approved
CyclothiazideDoxazosin may increase the hypotensive activities of Cyclothiazide.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Doxazosin.Approved
DabrafenibThe serum concentration of Doxazosin can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Doxazosin.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Doxazosin.Investigational
DarifenacinThe metabolism of Doxazosin can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineDoxazosin may increase the hypotensive activities of Darodipine.Experimental
DarunavirThe serum concentration of Doxazosin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Doxazosin.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Doxazosin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Doxazosin.Approved
DelavirdineThe metabolism of Doxazosin can be decreased when combined with Delavirdine.Approved
DeserpidineDoxazosin may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Doxazosin is combined with Desflurane.Approved
DesipramineThe metabolism of Doxazosin can be decreased when combined with Desipramine.Approved
DetomidineDoxazosin may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Doxazosin.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dexmedetomidine.Approved, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Doxazosin.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Doxazosin.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Diclofenamide.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Doxazosin.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Doxazosin.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Doxazosin.Approved
DihydralazineDoxazosin may increase the hypotensive activities of Dihydralazine.Investigational
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Doxazosin.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Doxazosin.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Doxazosin can be decreased when combined with Diphenhydramine.Approved
DipivefrinDoxazosin may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dipyridamole.Approved
DobutamineDoxazosin may decrease the vasoconstricting activities of Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Doxazosin.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Doxazosin.Approved, Investigational, Vet Approved
DorzolamideDoxazosin may increase the hypotensive activities of Dorzolamide.Approved
DotarizineDoxazosin may increase the hypotensive activities of Dotarizine.Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Doxazosin.Approved, Investigational
DronedaroneThe metabolism of Doxazosin can be decreased when combined with Dronedarone.Approved
DroxidopaDoxazosin may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineDoxazosin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Doxazosin.Approved
EfavirenzThe metabolism of Doxazosin can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineDoxazosin may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Doxazosin.Approved, Investigational
EliglustatThe metabolism of Doxazosin can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Doxazosin.Approved, Vet Approved
EnalaprilatDoxazosin may increase the hypotensive activities of Enalaprilat.Approved
EperisoneDoxazosin may increase the hypotensive activities of Eperisone.Approved, Investigational
EphedrineDoxazosin may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Doxazosin.Approved, Investigational
EpinephrineDoxazosin may decrease the vasoconstricting activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Doxazosin is combined with Eplerenone.Approved
EpoprostenolDoxazosin may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Doxazosin is combined with Eprosartan.Approved
ErgotamineDoxazosin may decrease the vasoconstricting activities of Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Doxazosin.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Doxazosin.Approved, Vet Approved
Eslicarbazepine acetateThe metabolism of Doxazosin can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
EsomeprazoleThe metabolism of Doxazosin can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Doxazosin.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Doxazosin.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Doxazosin.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Doxazosin is combined with Etacrynic acid.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Doxazosin.Approved
EtilefrineDoxazosin may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Doxazosin.Approved
EtravirineThe metabolism of Doxazosin can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Doxazosin.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Doxazosin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Felodipine.Approved, Investigational
FendilineDoxazosin may increase the hypotensive activities of Fendiline.Withdrawn
FenoldopamDoxazosin may increase the hypotensive activities of Fenoldopam.Approved
FenoterolDoxazosin may decrease the vasoconstricting activities of Fenoterol.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Doxazosin.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Doxazosin.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Doxazosin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Doxazosin is combined with Fimasartan.Approved
FluconazoleThe metabolism of Doxazosin can be decreased when combined with Fluconazole.Approved
FlunarizineDoxazosin may increase the hypotensive activities of Flunarizine.Approved
FluoxetineThe metabolism of Doxazosin can be decreased when combined with Fluoxetine.Approved, Vet Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Doxazosin.Approved
FluvoxamineThe metabolism of Doxazosin can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolDoxazosin may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Doxazosin.Approved
FosphenytoinThe metabolism of Doxazosin can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Doxazosin.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Furosemide.Approved, Vet Approved
GabapentinDoxazosin may increase the hypotensive activities of Gabapentin.Approved, Investigational
GallopamilDoxazosin may increase the hypotensive activities of Gallopamil.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Doxazosin.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Doxazosin.Approved
GemfibrozilThe metabolism of Doxazosin can be decreased when combined with Gemfibrozil.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Doxazosin.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Doxazosin.Withdrawn
GuanabenzDoxazosin may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Doxazosin.Approved
GuanethidineDoxazosin may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Guanfacine.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Doxazosin.Approved
HalothaneThe risk or severity of adverse effects can be increased when Doxazosin is combined with Halothane.Approved, Vet Approved
HexamethoniumDoxazosin may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Doxazosin.Approved
HexoprenalineDoxazosin may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineDoxazosin may decrease the vasoconstricting activities of Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Doxazosin.Approved
HydralazineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Doxazosin.Approved, Vet Approved
HydroflumethiazideDoxazosin may increase the hypotensive activities of Hydroflumethiazide.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Doxazosin.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Doxazosin.Approved
IloprostIloprost may increase the hypotensive activities of Doxazosin.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Doxazosin.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Doxazosin.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Doxazosin.Approved
IndapamideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Indapamide.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Doxazosin.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Doxazosin.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Doxazosin.Approved, Investigational
IndoraminDoxazosin may increase the antihypertensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Doxazosin.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Doxazosin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Doxazosin is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Doxazosin.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Doxazosin.Approved
IsoetarineDoxazosin may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Doxazosin is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Doxazosin can be decreased when combined with Isoniazid.Approved
IsoprenalineDoxazosin may decrease the vasoconstricting activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Doxazosin is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Doxazosin is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Doxazosin.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Doxazosin.Approved, Vet Approved
KetanserinDoxazosin may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Doxazosin.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Doxazosin.Approved, Investigational
LabetalolDoxazosin may increase the antihypertensive activities of Labetalol.Approved
LacidipineDoxazosin may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Doxazosin.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Doxazosin.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Doxazosin.Approved, Investigational
LatanoprostDoxazosin may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Doxazosin.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Doxazosin.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Doxazosin.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Doxazosin.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Doxazosin.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Doxazosin is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Levobupivacaine.Approved
LevodopaDoxazosin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Doxazosin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Doxazosin.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Doxazosin is combined with Levosimendan.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Doxazosin.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Lisinopril.Approved, Investigational
LofexidineDoxazosin may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Doxazosin.Approved
LopinavirThe metabolism of Doxazosin can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Doxazosin can be decreased when combined with Lorcaserin.Approved
LosartanThe risk or severity of adverse effects can be increased when Doxazosin is combined with Losartan.Approved
LuliconazoleThe serum concentration of Doxazosin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Doxazosin can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Doxazosin can be decreased when combined with Lumefantrine.Approved
MacitentanDoxazosin may increase the hypotensive activities of Macitentan.Approved
Magnesium SulfateDoxazosin may increase the hypotensive activities of Magnesium Sulfate.Approved, Vet Approved
ManidipineDoxazosin may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Doxazosin is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Doxazosin.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Mecamylamine.Approved
MedetomidineDoxazosin may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MephentermineDoxazosin may decrease the vasoconstricting activities of Mephentermine.Approved
MetaraminolDoxazosin may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethadoneThe metabolism of Doxazosin can be decreased when combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Doxazosin.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Doxazosin.Approved
MethotrimeprazineThe metabolism of Doxazosin can be decreased when combined with Methotrimeprazine.Approved
MethoxamineDoxazosin may decrease the vasoconstricting activities of Methoxamine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Doxazosin.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Doxazosin is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Doxazosin.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Doxazosin.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Doxazosin.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Doxazosin.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Doxazosin is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Doxazosin.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Doxazosin.Approved, Investigational
MetyrosineDoxazosin may increase the hypotensive activities of Metyrosine.Approved
MibefradilDoxazosin may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Doxazosin.Approved, Illicit
MidodrineDoxazosin may decrease the vasoconstricting activities of Midodrine.Approved
MinaprineMinaprine may increase the hypotensive activities of Doxazosin.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Doxazosin.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Doxazosin.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Doxazosin.Approved, Investigational
MoclobemideThe metabolism of Doxazosin can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Doxazosin can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Doxazosin.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Doxazosin.Approved, Investigational
MoxonidineDoxazosin may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Doxazosin.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nabilone.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
NaftopidilDoxazosin may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Doxazosin.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Doxazosin.Approved, Vet Approved
NaphazolineDoxazosin may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nebivolol.Approved, Investigational
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Doxazosin.Approved
NesiritideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nesiritide.Approved, Investigational
NevirapineThe metabolism of Doxazosin can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Doxazosin.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Doxazosin.Approved
NifedipineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nifedipine.Approved
NiguldipineDoxazosin may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Doxazosin.Approved, Investigational
NiludipineDoxazosin may increase the hypotensive activities of Niludipine.Experimental
NilvadipineDoxazosin may increase the hypotensive activities of Nilvadipine.Approved
NimesulideDoxazosin may increase the hypotensive activities of Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Doxazosin.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Doxazosin.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Doxazosin.Approved
NitrendipineDoxazosin may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Doxazosin.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Doxazosin.Approved
NorepinephrineDoxazosin may decrease the vasoconstricting activities of Norepinephrine.Approved
NylidrinDoxazosin may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabDoxazosin may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Doxazosin.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Doxazosin.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Doxazosin.Approved, Investigational
OlodaterolDoxazosin may decrease the vasoconstricting activities of Olodaterol.Approved
OmapatrilatDoxazosin may increase the hypotensive activities of Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Doxazosin.Approved
OmeprazoleThe metabolism of Doxazosin can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrciprenalineDoxazosin may decrease the vasoconstricting activities of Orciprenaline.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Doxazosin.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
OxymetazolineDoxazosin may decrease the vasoconstricting activities of Oxymetazoline.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Doxazosin.Approved, Vet Approved
PanobinostatThe serum concentration of Doxazosin can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Doxazosin can be decreased when combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Doxazosin.Approved
ParoxetineThe metabolism of Doxazosin can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Doxazosin.Approved
Peginterferon alfa-2bThe serum concentration of Doxazosin can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Doxazosin.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Doxazosin.Approved, Vet Approved
PentoliniumDoxazosin may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Doxazosin.Approved, Investigational
PerhexilineDoxazosin may increase the hypotensive activities of Perhexiline.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Doxazosin.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Doxazosin.Withdrawn
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Doxazosin.Approved
PhenoxybenzamineDoxazosin may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Doxazosin.Withdrawn
PhentolamineDoxazosin may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineDoxazosin may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineDoxazosin may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Doxazosin can be increased when combined with Phenytoin.Approved, Vet Approved
PinacidilDoxazosin may increase the hypotensive activities of Pinacidil.Withdrawn
PinaveriumDoxazosin may increase the hypotensive activities of Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Doxazosin is combined with Pipamperone.Approved
PirbuterolDoxazosin may decrease the vasoconstricting activities of Pirbuterol.Approved
PirlindolePirlindole may increase the hypotensive activities of Doxazosin.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Doxazosin.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Doxazosin.Withdrawn
PolythiazideDoxazosin may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Doxazosin.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Doxazosin.Approved
PractololPractolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Doxazosin is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Doxazosin.Approved
PrazosinPrazosin may increase the antihypertensive activities of Doxazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Doxazosin.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Doxazosin.Approved, Vet Approved
PregabalinDoxazosin may increase the hypotensive activities of Pregabalin.Approved, Illicit, Investigational
PrenylamineDoxazosin may increase the hypotensive activities of Prenylamine.Withdrawn
PrimidonePrimidone may increase the hypotensive activities of Doxazosin.Approved, Vet Approved
ProcaterolDoxazosin may decrease the vasoconstricting activities of Procaterol.Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Doxazosin.Approved, Vet Approved
PromazineThe metabolism of Doxazosin can be decreased when combined with Promazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Doxazosin is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Doxazosin.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Doxazosin.Approved
PseudoephedrineDoxazosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Doxazosin can be decreased when combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Doxazosin.Approved
RacepinephrineDoxazosin may decrease the vasoconstricting activities of Racepinephrine.Approved
RactopamineDoxazosin may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Doxazosin.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Doxazosin.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Doxazosin.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Doxazosin.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Doxazosin.Approved
RescinnamineDoxazosin may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Doxazosin.Approved
RifampicinThe metabolism of Doxazosin can be increased when combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Doxazosin.Approved, Investigational
RilmenidineDoxazosin may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Doxazosin is combined with Riociguat.Approved
RisedronateDoxazosin may increase the hypotensive activities of Risedronate.Approved, Investigational
RisperidoneDoxazosin may increase the hypotensive activities of Risperidone.Approved, Investigational
RitobegronDoxazosin may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineDoxazosin may decrease the vasoconstricting activities of Ritodrine.Approved
RitonavirThe metabolism of Doxazosin can be decreased when combined with Ritonavir.Approved, Investigational
RituximabDoxazosin may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Doxazosin.Approved
RolapitantThe metabolism of Doxazosin can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Doxazosin.Approved, Investigational
RomifidineDoxazosin may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleThe metabolism of Doxazosin can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Doxazosin.Withdrawn
SalbutamolDoxazosin may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Doxazosin.Approved, Vet Approved
SalmeterolDoxazosin may decrease the vasoconstricting activities of Salmeterol.Approved
SaprisartanDoxazosin may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Doxazosin.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Doxazosin.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Doxazosin.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Doxazosin.Approved
SertralineThe metabolism of Doxazosin can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Doxazosin is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Doxazosin.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Doxazosin.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Doxazosin.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Doxazosin.Approved, Investigational
SitaxentanDoxazosin may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Doxazosin is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Doxazosin.Approved
SolabegronDoxazosin may decrease the vasoconstricting activities of Solabegron.Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Doxazosin.Approved, Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Doxazosin.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Doxazosin.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Doxazosin.Experimental
SpiraprilDoxazosin may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Doxazosin.Approved
SR 58611Doxazosin may decrease the vasoconstricting activities of SR 58611.Investigational
StiripentolThe metabolism of Doxazosin can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Doxazosin is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Sufentanil.Approved, Investigational
SynephrineDoxazosin may decrease the vasoconstricting activities of Synephrine.Experimental
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Doxazosin.Approved, Investigational
TadalafilTadalafil may increase the hypotensive activities of Doxazosin.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Doxazosin.Approved
TamsulosinDoxazosin may increase the antihypertensive activities of Tamsulosin.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Doxazosin.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Doxazosin.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Doxazosin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Doxazosin is combined with Telmisartan.Approved, Investigational
TemocaprilDoxazosin may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Doxazosin.Approved
TerazosinDoxazosin may increase the antihypertensive activities of Terazosin.Approved
TerbinafineThe metabolism of Doxazosin can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineDoxazosin may decrease the vasoconstricting activities of Terbutaline.Approved
TerlipressinDoxazosin may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Doxazosin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Doxazosin.Approved, Vet Approved
ThioridazineThe metabolism of Doxazosin can be decreased when combined with Thioridazine.Approved
TiboloneDoxazosin may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Doxazosin.Approved
TiclopidineThe metabolism of Doxazosin can be decreased when combined with Ticlopidine.Approved
TicrynafenDoxazosin may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
TipranavirThe metabolism of Doxazosin can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Tizanidine.Approved
TolazolineDoxazosin may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Doxazosin is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidDoxazosin may increase the hypotensive activities of Tolfenamic Acid.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Doxazosin.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Doxazosin.Approved
TopiramateThe metabolism of Doxazosin can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Doxazosin.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Doxazosin.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Doxazosin.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Doxazosin.Approved
TranilastDoxazosin may increase the hypotensive activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Doxazosin.Experimental
TranylcypromineThe metabolism of Doxazosin can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Doxazosin.Approved
TravoprostTravoprost may increase the hypotensive activities of Doxazosin.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Doxazosin.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Doxazosin.Approved
TrichlormethiazideDoxazosin may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinDoxazosin may increase the antihypertensive activities of Trimazosin.Experimental
TrimethaphanDoxazosin may increase the hypotensive activities of Trimethaphan.Approved
TulobuterolDoxazosin may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Doxazosin.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Doxazosin.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Doxazosin.Approved
UnoprostoneDoxazosin may increase the hypotensive activities of Unoprostone.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Doxazosin.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Doxazosin.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Doxazosin.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Doxazosin.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Doxazosin.Approved
VerapamilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Doxazosin.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Doxazosin.Approved, Investigational
VinpocetineDoxazosin may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Doxazosin.Approved
VoriconazoleThe metabolism of Doxazosin can be decreased when combined with Voriconazole.Approved, Investigational
XylazineDoxazosin may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineDoxazosin may increase the hypotensive activities of Xylometazoline.Approved
YM-178Doxazosin may decrease the vasoconstricting activities of YM-178.Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Doxazosin.Approved, Vet Approved
ZiconotideDoxazosin may increase the hypotensive activities of Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Doxazosin.Approved
ZiprasidoneThe metabolism of Doxazosin can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Take without regard to meals.
References
Synthesis Reference

K. S. Keshava Murthy, Gamini Weeratunga, Tianhao Zhou, Bhaskar Reddy Guntoori, “Process for the manufacture of intermediates suitable to make doxazosin, terazosin, prazosin, tiodazosin and related antihypertensive medicines.” U.S. Patent US5919931, issued September, 1986.

US5919931
General References
  1. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [PubMed:12461301 ]
External Links
ATC CodesC02CA04
AHFS Codes
  • 24:20.00
PDB EntriesNot Available
FDA labelDownload (511 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9627
Caco-2 permeable+0.7863
P-glycoprotein substrateSubstrate0.7303
P-glycoprotein inhibitor INon-inhibitor0.7391
P-glycoprotein inhibitor IINon-inhibitor0.9528
Renal organic cation transporterNon-inhibitor0.6909
CYP450 2C9 substrateNon-substrate0.9011
CYP450 2D6 substrateNon-substrate0.8195
CYP450 3A4 substrateSubstrate0.7228
CYP450 1A2 substrateNon-inhibitor0.8293
CYP450 2C9 inhibitorNon-inhibitor0.9161
CYP450 2D6 inhibitorNon-inhibitor0.9533
CYP450 2C19 inhibitorNon-inhibitor0.9084
CYP450 3A4 inhibitorNon-inhibitor0.8002
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9078
Ames testNon AMES toxic0.5648
CarcinogenicityNon-carcinogens0.8905
BiodegradationNot ready biodegradable0.9854
Rat acute toxicity2.1954 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8602
hERG inhibition (predictor II)Inhibitor0.823
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pfizer inc
  • Pfizer laboratories div pfizer inc
  • Actavis elizabeth llc
  • Apotex inc
  • Dava pharmaceuticals inc
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Mylan pharmaceuticals inc
  • Pliva inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tablet, multilayer, extended releaseOral4 mg/1
Tablet, multilayer, extended releaseOral8 mg/1
TabletOral1 mg
Kit; tabletOral
TabletOral2 mg
TabletOral4 mg
TabletOral1 mg/1
TabletOral2 mg/1
TabletOral4 mg/1
TabletOral8 mg/1
Prices
Unit descriptionCostUnit
Cardura XL 4 mg 24 Hour tablet2.22USD tablet
Cardura xl 8 mg tablet2.04USD tablet
Cardura xl 4 mg tablet1.94USD tablet
Cardura 8 mg tablet1.93USD tablet
Cardura 4 mg tablet1.89USD tablet
Cardura 2 mg tablet1.81USD tablet
Cardura 1 mg tablet1.72USD tablet
Doxazosin mesylate 8 mg tablet1.04USD tablet
Cardura 4 mg Tablet1.0USD tablet
Doxazosin mesylate 4 mg tablet0.99USD tablet
Doxazosin mesylate 1 mg tablet0.94USD tablet
Doxazosin mesylate 2 mg tablet0.94USD tablet
Cardura 2 mg Tablet0.77USD tablet
Cardura 1 mg Tablet0.64USD tablet
Apo-Doxazosin 4 mg Tablet0.56USD tablet
Mylan-Doxazosin 4 mg Tablet0.56USD tablet
Novo-Doxazosin 4 mg Tablet0.56USD tablet
Pms-Doxazosin 4 mg Tablet0.56USD tablet
Apo-Doxazosin 2 mg Tablet0.43USD tablet
Mylan-Doxazosin 2 mg Tablet0.43USD tablet
Novo-Doxazosin 2 mg Tablet0.43USD tablet
Pms-Doxazosin 2 mg Tablet0.43USD tablet
Apo-Doxazosin 1 mg Tablet0.36USD tablet
Mylan-Doxazosin 1 mg Tablet0.36USD tablet
Novo-Doxazosin 1 mg Tablet0.36USD tablet
Pms-Doxazosin 1 mg Tablet0.36USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point289-290 °CNot Available
water solubility24 mg/LNot Available
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.79 mg/mLALOGPS
logP2.53ALOGPS
logP2.14ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)12.67ChemAxon
pKa (Strongest Basic)7.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area112.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity121.64 m3·mol-1ChemAxon
Polarizability46.63 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Quinazolinamine
  • Quinazoline
  • Benzodioxane
  • Benzo-p-dioxin
  • Benzo-1,4-dioxane
  • Dialkylarylamine
  • Anisole
  • Aminopyrimidine
  • Alkyl aryl ether
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Primary aromatic amine
  • Para-dioxin
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Yono M, Foster HE Jr, Shin D, Takahashi W, Pouresmail M, Latifpour J: Doxazosin-induced up-regulation of alpha 1A-adrenoceptor mRNA in the rat lower urinary tract. Can J Physiol Pharmacol. 2004 Oct;82(10):872-8. [PubMed:15573147 ]
  2. Michel MC, Grubbel B, Taguchi K, Verfurth F, Otto T, Kropfl D: Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8. [PubMed:8736427 ]
  3. Roehrborn CG, Schwinn DA: Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004 Mar;171(3):1029-35. [PubMed:14767264 ]
  4. Ishizuka O, Pandita RK, Mattiasson A, Steers WD, Andersson KE: Stimulation of bladder activity by volume, L-dopa and capsaicin in normal conscious rats--effects of spinal alpha 1-adrenoceptor blockade. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):787-93. [PubMed:9205965 ]
  5. Bae JH, Jung PB, Lee JG: The effects of alpha-adrenoceptor antagonists on the urethral perfusion pressure of the female rat. BJU Int. 2005 Nov;96(7):1131-5. [PubMed:16225542 ]
  6. Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. [PubMed:19002123 ]
  7. Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006 Nov;152(5):842-50. [PubMed:17070143 ]
  8. Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36 Suppl 1:35-41; discussion 65. [PubMed:10393471 ]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Lepor H: Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90. [PubMed:18231614 ]
  2. Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. [PubMed:19002123 ]
  3. Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006 Nov;152(5):842-50. [PubMed:17070143 ]
  4. Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36 Suppl 1:35-41; discussion 65. [PubMed:10393471 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Lepor H: Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90. [PubMed:18231614 ]
  2. Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. [PubMed:19002123 ]
  3. Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006 Nov;152(5):842-50. [PubMed:17070143 ]
  4. Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36 Suppl 1:35-41; discussion 65. [PubMed:10393471 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly.
Gene Name:
KCNH6
Uniprot ID:
Q9H252
Molecular Weight:
109923.705 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly.
Gene Name:
KCNH7
Uniprot ID:
Q9NS40
Molecular Weight:
134998.525 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
  2. Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33. [PubMed:19806783 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on November 03, 2016 12:18